Perrigo's generics split is back on the docket, thanks to $1.55B Altaris offer
Perrigo is selling its prescription generics business to Altaris Capital Partners for $1.55 billion. The generics unit, which recently nabbed approval for a copycat version of Teva's ProAir HFA inhaler, will establish itself as a standalone company, investment firm Altaris said. The deal is expected to close by the end of the third quarter.
Murray Kessler Rosen Katz Garikai Nyaruwata Goldman Sachs Altaris Capital Partners Uncover Rare Disease Insights
Source: fiercepharma.com